143 related articles for article (PubMed ID: 28007545)
1. Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties.
Levet V; Merlos R; Rosière R; Amighi K; Wauthoz N
Int J Pharm; 2017 Jan; 517(1-2):359-372. PubMed ID: 28007545
[TBL] [Abstract][Full Text] [Related]
2. Development of controlled-release cisplatin dry powders for inhalation against lung cancers.
Levet V; Rosière R; Merlos R; Fusaro L; Berger G; Amighi K; Wauthoz N
Int J Pharm; 2016 Dec; 515(1-2):209-220. PubMed ID: 27737810
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy.
Rosière R; Van Woensel M; Mathieu V; Langer I; Mathivet T; Vermeersch M; Amighi K; Wauthoz N
Int J Pharm; 2016 Mar; 501(1-2):148-59. PubMed ID: 26850313
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
6. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
7. Lecithin/TPGS-based spray-dried self-microemulsifying drug delivery systems: In vitro pulmonary deposition and cytotoxicity.
Ishak RA; Osman R
Int J Pharm; 2015 May; 485(1-2):249-60. PubMed ID: 25772421
[TBL] [Abstract][Full Text] [Related]
8. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs.
Fiegel J; Fu J; Hanes J
J Control Release; 2004 May; 96(3):411-23. PubMed ID: 15120898
[TBL] [Abstract][Full Text] [Related]
9. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability.
Maretti E; Rustichelli C; Romagnoli M; Balducci AG; Buttini F; Sacchetti F; Leo E; Iannuccelli V
Int J Pharm; 2016 Sep; 511(1):669-679. PubMed ID: 27473279
[TBL] [Abstract][Full Text] [Related]
10. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice.
Duret C; Wauthoz N; Merlos R; Goole J; Maris C; Roland I; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2012 Aug; 81(3):627-34. PubMed ID: 22538097
[TBL] [Abstract][Full Text] [Related]
12. Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation.
Cuvelier B; Eloy P; Loira-Pastoriza C; Ucakar B; Sanogo AA; Dupont-Gillain C; Vanbever R
Int J Pharm; 2015 Nov; 495(2):981-90. PubMed ID: 26456267
[TBL] [Abstract][Full Text] [Related]
13. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections.
Matinkhoo S; Lynch KH; Dennis JJ; Finlay WH; Vehring R
J Pharm Sci; 2011 Dec; 100(12):5197-205. PubMed ID: 22020816
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation.
Tang Y; Zhang H; Lu X; Jiang L; Xi X; Liu J; Zhu J
Drug Deliv; 2015; 22(5):608-18. PubMed ID: 24299495
[TBL] [Abstract][Full Text] [Related]
15. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
[TBL] [Abstract][Full Text] [Related]
16. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
17. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
18. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.
Garcia-Contreras L; Padilla-Carlin DJ; Sung J; VerBerkmoes J; Muttil P; Elbert K; Peloquin C; Edwards D; Hickey A
J Pharm Sci; 2017 Jan; 106(1):331-337. PubMed ID: 27842973
[TBL] [Abstract][Full Text] [Related]
20. New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.
Rosière R; Gelbcke M; Mathieu V; Van Antwerpen P; Amighi K; Wauthoz N
Int J Oncol; 2015 Sep; 47(3):1131-42. PubMed ID: 26201404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]